Tagged with Biotech,

Turkey Dr Ferhat Farsi, CEO and founding partner of CinnaGen İlaç, shares the company’s plans to become Turkey’s leading biotech entity and gives insights into the group’s international expansion plans. He highlights the potential of for biotechnology and rare disease therapies in the Turkish market, while also acknowledging the obstacles for…

Spain This map of the distribution of biotech companies throughout Spain shows that the country’s most significant biotech clusters are in Catalonia (23.3% of all biotech companies), followed by Madrid (18.7%), Valencia (10%) and the Basque Country (8.8%).   The number of active biotech companies in Spain peaked in 2011 at 660 and…

Spain Spain’s biotech scene is on the rise. In 2016 alone, the nation had a total of 651 biotech companies, with a total of 33 commencing operations in 2017. Despite these quite modest numbers in comparison to more well-established global biotech hubs, they have been accompanied by some extremely encouraging exits.…

Korea Seung-Kyou Lee, vice-president of Korea Bio gives his assessment on the current landscape for biotech firms in Korea. He also discusses Korea Bio’s programme to create a further 1000 biotech firms in Korea within three years.   We are at a critical juncture. If we fail to catch up with…

France Christophe Cizeron, president of Lyonbiopole, discusses the important economic and industrial position of the research cluster in the Rhone-Alps Region as well as the challenges posed by domestic and international competition.   Between 2007-2016, the number of biotech companies doubled in the Lyon region and there was a sharp increase…

Korea Sunyoung Kim, CEO and founder of ViroMed, reveals his strategy for conquering the US market and the feasibility of his ambitions for ViroMed to become the biotech company with the largest revenues from gene therapy by 2025. He also discusses the areas within the Korean biotech sphere that must develop…

Singapore Dr Charles Stacey, president and CEO of Brain Health company Cerecin, formerly Accera, discusses the rebrand, new investment, the company’s relocation to Asia, and the upcoming rollout of a global Phase III clinical trial for its innovative new Alzheimer’s drug.   As a small, innovative biotech company, we are looking…

Korea In an exclusive interview, Tae-Han Kim, president and CEO of Samsung Biologics, documents his strategy for expanding Samsung’s operations into biologics, and how Samsung Biologics has rapidly become one of the leading Contract Development Manufacturing Organisations (CDMO) in the market in only seven years. Dr Kim also provides his assessment…

Hong Kong Energetically touting itself as “Asia’s World City” as well as a connector between East and West with its inextricable links to both mainland China and the international community, Hong Kong is today seeking to augment her position as a global financial center by transforming herself into a biotech and biomedical…

Korea Jongmoon Kim, CEO of ToolGen discusses the potential for their CRISPR technology to revolutionize not only therapy for genetic illnesses, but also agriculture. Kim explains his move from information technology to biotechnology and the importance of building international partnerships across the industry.   CRISPR simplifies some of the complex tasks…

Korea JungTae Park, senior managing director of KoBIA (Korea Biomedicine Industry Association), describes the achievements of the association as a bridge between industry and government. He also highlights the potential of the Korean biopharmaceutical industry to become a global leader in the field.   Our priority is to support the globalization…

Biotech Pfizer has teamed up with Bain Capital to launch Cerevel Therapeutics, a biopharmaceutical company based in Boston that will focus on developing treatments for a number of central nervous system (CNS) disorders. It has almost been a year since Pfizer announced that they were to cease R&D in new neuroscience…